Impact of skeletal complications on patients' quality of life, mobility, and functional independence
- PMID: 18392862
- DOI: 10.1007/s00520-008-0418-0
Impact of skeletal complications on patients' quality of life, mobility, and functional independence
Erratum in
- Support Care Cancer. 2008 Oct;16(10):1201
Abstract
Introduction: Skeletal-related events (SREs) from malignant bone disease cause considerable morbidity and can dramatically reduce patients' quality of life.
Discussion: Pathologic fractures often require surgical intervention and palliative radiotherapy. Thus, patients suffer impaired mobility, loss of functional independence, and diminished health-related quality of life (HRQOL). Bisphosphonates can delay the onset and reduce the incidence of SREs and have become the standard of care for the treatment of malignant bone disease; however, minimal information on the effects of bisphosphonate treatment on HRQOL is available. Targeted HRQOL assessments for patients with malignant bone disease are currently under development and are discussed herein.
Similar articles
-
Prognostic factors for skeletal complications from metastatic bone disease in breast cancer.Breast Cancer Res Treat. 2010 Oct;123(3):767-79. doi: 10.1007/s10549-010-0981-1. Epub 2010 Jun 24. Breast Cancer Res Treat. 2010. PMID: 20574672
-
Bisphosphonates: reducing the risk of skeletal complications from bone metastasis.Breast. 2007 Dec;16 Suppl 3:S16-20. doi: 10.1016/j.breast.2007.10.005. Epub 2007 Nov 26. Breast. 2007. PMID: 18032044 Review.
-
Predicting skeletal complications in metastatic breast cancer raises challenges.Breast Cancer Res Treat. 2010 Oct;123(3):781-3. doi: 10.1007/s10549-010-1104-8. Epub 2010 Aug 6. Breast Cancer Res Treat. 2010. PMID: 20690039 Free PMC article. No abstract available.
-
Optimal management of metastatic bone disease.Eur J Oncol Nurs. 2007;11 Suppl 2:S32-7. doi: 10.1016/j.ejon.2007.07.003. Epub 2007 Sep 4. Eur J Oncol Nurs. 2007. PMID: 17804294 Review.
-
Clinical benefit of zoledronic acid for the prevention of skeletal complications in advanced prostate cancer.Clin Prostate Cancer. 2005 Jun;4(1):31-7. doi: 10.3816/cgc.2005.n.009. Clin Prostate Cancer. 2005. PMID: 15992459 Clinical Trial.
Cited by
-
Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer.Clin Med Insights Oncol. 2016 Mar 23;10(Suppl 1):11-9. doi: 10.4137/CMO.S30751. eCollection 2016. Clin Med Insights Oncol. 2016. PMID: 27042152 Free PMC article. Review.
-
Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.Eur Urol. 2015 Oct;68(4):570-7. doi: 10.1016/j.eururo.2015.04.032. Epub 2015 May 16. Eur Urol. 2015. PMID: 25985882 Free PMC article.
-
[Perioperative clinical characteristics of patients with pathological fracture of proximal femur].Beijing Da Xue Xue Bao Yi Xue Ban. 2019 Oct 18;51(5):875-880. doi: 10.19723/j.issn.1671-167X.2019.05.014. Beijing Da Xue Xue Bao Yi Xue Ban. 2019. PMID: 31624392 Free PMC article. Chinese.
-
Phase I trial with a combination of docetaxel and ¹⁵³Sm-lexidronam in patients with castration-resistant metastatic prostate cancer.Urol Oncol. 2011 Nov-Dec;29(6):670-5. doi: 10.1016/j.urolonc.2009.10.003. Epub 2009 Dec 4. Urol Oncol. 2011. PMID: 19962920 Free PMC article. Clinical Trial.
-
Efficacy and Effect of Cabozantinib on Bone Metastases in Treatment-naive Castration-resistant Prostate Cancer.Clin Genitourin Cancer. 2020 Aug;18(4):332-339.e2. doi: 10.1016/j.clgc.2019.10.019. Epub 2020 Mar 7. Clin Genitourin Cancer. 2020. PMID: 32299729 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical